SH2D7 Activators are a diverse set of chemical compounds that influence cellular signaling pathways, indirectly leading to the enhancement of SH2D7's functional activity. Forskolin and Dibutyryl-cAMP, through the elevation of intracellular cAMP levels, indirectly contribute to SH2D7 activation by stimulating protein kinase A (PKA), which in turn may target SH2D7 for phosphorylation. Similarly, Okadaic Acid enhances the phosphorylation status within cells by inhibiting protein phosphatases PP1 and PP2A, potentially resulting in the increased activity of SH2D7 through enhanced phosphorylation. Phorbol 12-myristate 13-acetate (PMA) functions as a PKC activator and Ionomycin serves as a calcium ionophore, both leading to the activation of kinases that may phosphorylate SH2D7, thereby amplifying its activity. The action of Epigallocatechin Gallate (EGCG) as a kinase inhibitor could also improve SH2D7's functional role by reducing competitive phosphorylation.
Furthermore, the involvement of calcium signaling in SH2D7 activation is highlighted by the use of compounds like Thapsigargin and A23187, both of which increase intracellular calcium levels, potentially triggering calcium-dependent kinases to phosphorylate and activate SH2D7. Calmodulin, upon binding to calcium, activates an array of kinases and phosphatases that could modify the phosphorylation state of SH2D7, leading to its enhanced activity. In the context of lipid signaling, Sphingosine-1-phosphate can activate G protein-coupled pathways thatmay culminate in the phosphorylation and activation of SH2D7. The PI3K inhibitors LY294002 and Wortmannin disrupt PI3K-dependent signaling, which might result in the compensatory activation of pathways that upregulate SH2D7 activity. Collectively, these activators, by modulating kinase and phosphatase activities, calcium levels, and lipid signaling, orchestrate a complex network of intracellular events that converge to potentiate the functional capacity of SH2D7 without directly increasing its expression or requiring direct binding interactions.
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin raises intracellular cAMP levels, which can activate protein kinase A (PKA). PKA, in turn, may phosphorylate proteins including SH2D7, enhancing its function within cellular signaling pathways. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Okadaic Acid is a potent inhibitor of protein phosphatases PP1 and PP2A, leading to increased phosphorylation levels within the cell. This can indirectly enhance the phosphorylation status and activity of SH2D7. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA is a diacylglycerol analog that activates protein kinase C (PKC), which can lead to the phosphorylation of specific substrates, potentially including SH2D7, thereby enhancing its activity. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin is a calcium ionophore that raises intracellular calcium levels, which can activate calcium-dependent protein kinases that may phosphorylate and activate SH2D7. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG is a kinase inhibitor that can alter signaling pathways by inhibiting certain kinases that would otherwise compete with SH2D7 for phosphorylation sites, potentially enhancing SH2D7 activity. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $45.00 $130.00 $480.00 $4450.00 | 74 | |
Dibutyryl-cAMP is a cAMP analog that activates cAMP-dependent PKA. Activated PKA may phosphorylate SH2D7, leading to its increased activity. | ||||||
Calmodulin (human), (recombinant) | 73298-54-1 | sc-471287 | 1 mg | $232.00 | ||
Calmodulin, upon binding calcium, activates various kinases and phosphatases. This can lead to a change in the phosphorylation state of SH2D7, potentially enhancing its activity. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
Sphingosine-1-phosphate acts via G protein-coupled receptors to activate downstream kinases, which could include kinases that phosphorylate and enhance the activity of SH2D7. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin inhibits the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to an increase in cytosolic calcium levels, which may activate kinases that phosphorylate and enhance SH2D7 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that can alter signaling pathways, potentially leading to compensatory activation of alternative pathways that enhance SH2D7 activity. |